{"id":"W4412851462","doi":"10.1016/j.ajt.2025.07.1645","title":"TRANSCEND: A Phase 3 Trial of the Anti-CD38 Antibody Felzartamab in Kidney Transplant Recipients with Late Antibody-Mediated Rejection","year":2025,"lang":"en","type":"article","venue":"American Journal of Transplantation","topic":"Renal Transplantation Outcomes and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Antibody; Donor specific antibodies; Kidney transplant; Immunology; Kidney transplantation; Renal transplant; CD38; Kidney; Internal medicine; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001043965,0.001037917,0.001299419,0.000258892,0.0003106973,0.001040609,0.0007507553,0.0007524682,0.004559586],"category_scores_gemma":[0.0005634022,0.0002377545,0.001257032,0.0001705375,0.000660158,0.000977695,0.0003459759,0.003562509,0.0008648122],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006803121,"about_ca_system_score_gemma":0.0007236663,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000620747,"about_ca_topic_score_gemma":0.001873368,"domain_scores_codex":[0.9998111,0.00007107092,0.000006970342,0.00002564056,0.00002193078,0.00006340504],"domain_scores_gemma":[0.9996542,0.0000595347,0.00005523979,0.00003062726,0.00001849054,0.0001818465],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6188836,0.03025032,0.006204146,0.001162644,0.002081518,0.0006066877,0.0003411438,0.002859619,0.04091723,0.001298307,0.009297646,0.2860972],"study_design_scores_gemma":[0.6857717,0.2824498,0.01248553,0.0001034176,0.0007781426,0.0008441528,0.0001660667,0.00188828,0.006070645,0.0008787508,0.008507237,0.00005618432],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9913883,0.003242118,0.0005603777,0.0008533704,0.000224937,0.0005110439,0.0004399575,0.000156888,0.00262307],"genre_scores_gemma":[0.98963,0.002259983,0.001259063,0.001259911,0.0001959744,0.0005473155,0.001148838,0.00003848193,0.003660381],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004559586,"threshold_uncertainty_score":0.01525331,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009672929773026296,"score_gpt":0.32377201754455,"score_spread":0.3140990877715237,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}